Abstract | OBJECTIVE: RESULTS: Low-dose intravenous cyclophosphamide pulses (500 mg) were administered weekly in all patients. Twenty-four out of 25 patients attained a good response (after a mean of 11 days). Cyclophosphamide was well tolerated in all patients with only minor side effects. None of the patients experienced ovarian failure, cystitis or herpes zoster. CONCLUSIONS:
|
Authors | P C Ramos, M J Mendez, P R Ames, M A Khamashta, G R Hughes |
Journal | Clinical and experimental rheumatology
(Clin Exp Rheumatol)
1996 May-Jun
Vol. 14
Issue 3
Pg. 295-9
ISSN: 0392-856X [Print] Italy |
PMID | 8809444
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antirheumatic Agents
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Antirheumatic Agents
(administration & dosage, adverse effects)
- Child
- Cyclophosphamide
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Female
- Humans
- Injections, Intravenous
- Lupus Erythematosus, Systemic
(drug therapy)
- Male
- Mental Disorders
(drug therapy)
- Middle Aged
- Neurocognitive Disorders
(drug therapy)
- Retrospective Studies
- Treatment Outcome
|